StreetInsider.com News Articles

Form 4 Prestige Consumer Health For: Feb 11 Filed by: Zerillo Jeffrey

Fri, 13 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260213/26001263.html

Form 4 Prestige Consumer Health For: Feb 11 Filed by: Zerillo Jeffrey

Fri, 13 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260213/26001263.html

Form SCHEDULE 13G/A Prestige Consumer Health Filed by: ARIEL INVESTMENTS, LLC

Fri, 13 Feb 2026 10:53:00 -0500

si-local-file:///var/storage/secattach/20260213/25997284.html

Form SCHEDULE 13G/A Prestige Consumer Health Filed by: ARIEL INVESTMENTS, LLC

Fri, 13 Feb 2026 10:53:00 -0500

si-local-file:///var/storage/secattach/20260213/25997284.html

Form 144 Prestige Consumer Health Filed by: Zerillo Jeffrey

Wed, 11 Feb 2026 10:29:00 -0500

si-local-file:///var/storage/secattach/20260211/25981192.html

Form 144 Prestige Consumer Health Filed by: Zerillo Jeffrey

Wed, 11 Feb 2026 10:29:00 -0500

si-local-file:///var/storage/secattach/20260211/25981192.html

Presitge Brands (PBH) PT Lowered to $86 at Canaccord Genuity

Fri, 06 Feb 2026 06:27:00 -0500

Canaccord Genuity analyst Susan Anderson lowered the price target on Presitge Brands (NYSE: PBH) to $86.00 (from $88.00) while maintaining a Buy rating.

Prestige Brands (PBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Guidance

Thu, 05 Feb 2026 06:10:00 -0500

Prestige Brands (NYSE: PBH) reported Q3 EPS of $1.14, in-line with the analyst estimate of $1.14. Revenue for the quarter came in at $283.44 million versus the consensus estimate of $281.12 million.

GUIDANCE:

Prestige Brands sees FY2026 EPS of $4.54, versus the consensus of $4.56. Prestige Brands sees FY2026 revenue of $1.1 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Prestige Brands (PBH) click here.

Prestige Brands (PBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Guidance

Thu, 05 Feb 2026 06:10:00 -0500

Prestige Brands (NYSE: PBH) reported Q3 EPS of $1.14, in-line with the analyst estimate of $1.14. Revenue for the quarter came in at $283.44 million versus the consensus estimate of $281.12 million.

GUIDANCE:

Prestige Brands sees FY2026 EPS of $4.54, versus the consensus of $4.56. Prestige Brands sees FY2026 revenue of $1.1 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Prestige Brands (PBH) click here.

Form 10-Q Prestige Consumer Health For: Dec 31

Thu, 05 Feb 2026 06:10:00 -0500

si-local-file:///var/storage/secattach/20260205/25949898.html

Form 10-Q Prestige Consumer Health For: Dec 31

Thu, 05 Feb 2026 06:10:00 -0500

si-local-file:///var/storage/secattach/20260205/25949898.html

Form 8-K Prestige Consumer Health For: Feb 05

Thu, 05 Feb 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260205/25949851.html

Form 8-K Prestige Consumer Health For: Feb 05

Thu, 05 Feb 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260205/25949851.html

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

Thu, 05 Feb 2026 06:00:00 -0500

Revenue of $283.4 million in Q3, ahead of outlook
Diluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22
Repurchased approximately 0.8 million shares opportunistically in Q3
Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expected
Narrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS

TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025.

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

Thu, 05 Feb 2026 06:00:00 -0500

Revenue of $283.4 million in Q3, ahead of outlook
Diluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22
Repurchased approximately 0.8 million shares opportunistically in Q3
Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expected
Narrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS

TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025.

Form 4 Prestige Consumer Health For: Jan 06 Filed by: Rosado Jose Luis

Thu, 29 Jan 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260129/25916276.html

Form 4 Prestige Consumer Health For: Jan 06 Filed by: Rosado Jose Luis

Thu, 29 Jan 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260129/25916276.html

Form 3 Prestige Consumer Health For: Jan 06 Filed by: Rosado Jose Luis

Thu, 29 Jan 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260129/25916262.html

Form 3 Prestige Consumer Health For: Jan 06 Filed by: Rosado Jose Luis

Thu, 29 Jan 2026 16:01:00 -0500

si-local-file:///var/storage/secattach/20260129/25916262.html

Form D PREMIUM BRANDS HOLDINGS

Fri, 23 Jan 2026 13:46:00 -0500

si-local-file:///var/storage/secattach/20260123/25886399.html

Form D PREMIUM BRANDS HOLDINGS

Fri, 23 Jan 2026 13:46:00 -0500

si-local-file:///var/storage/secattach/20260123/25886399.html

Form D PREMIUM BRANDS HOLDINGS

Fri, 23 Jan 2026 13:46:00 -0500

si-local-file:///var/storage/secattach/20260123/25886399.html

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

Mon, 12 Jan 2026 08:00:00 -0500

TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

Mon, 12 Jan 2026 08:00:00 -0500

Wynnchurch Capital Exits Stampede Culinary Partners

Wed, 07 Jan 2026 12:05:00 -0500

ROSEMONT, Ill.--(BUSINESS WIRE)-- Wynnchurch Capital, L.P. (“Wynnchurch”), a leading middle market private equity firm, today announced the sale of Stampede Culinary Partners, Inc. (“Stampede” or the “Company”) to Premium Brands Holdings Corporation (“Premium Brands”) (TSX:PBH).

Headquartered in Bridgeview, Illinois, Stampede is a leading North American culinary solutions provider, with a specialized focus on sous vide solutions. With over three decades of experience, Stampede serves a blue-chip customer base across multiple channels, including restaurants, retail, and foodservice distribution. The Company has grown significantly through organic expansion, strategic acquisitions, and continued investments in capacity and capabilities, resulting in an industry-leading